[go: up one dir, main page]

WO2006074963A3 - Systeme de transfert de gene lentiviral pour une reparation de l'arn mediee par les ribozymes - Google Patents

Systeme de transfert de gene lentiviral pour une reparation de l'arn mediee par les ribozymes Download PDF

Info

Publication number
WO2006074963A3
WO2006074963A3 PCT/EP2006/000358 EP2006000358W WO2006074963A3 WO 2006074963 A3 WO2006074963 A3 WO 2006074963A3 EP 2006000358 W EP2006000358 W EP 2006000358W WO 2006074963 A3 WO2006074963 A3 WO 2006074963A3
Authority
WO
WIPO (PCT)
Prior art keywords
vlv
plasmid
sequence encoding
ribozyme
repair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/000358
Other languages
English (en)
Other versions
WO2006074963A2 (fr
Inventor
Michael Foley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENEERING GmbH
Original Assignee
GENEERING GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENEERING GmbH filed Critical GENEERING GmbH
Publication of WO2006074963A2 publication Critical patent/WO2006074963A2/fr
Publication of WO2006074963A3 publication Critical patent/WO2006074963A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un système de transfert de gène lentiviral recombiné plus sûr et efficace qui permet une réparation médiée par les ribozymes d'un ARN cible dans des cellules en division ou non, sur la base d'un lentivirus Visna (VLV), lequel système comprend: (a) un premier plasmide comprenant une séquence qui code le VLV Gag, (b) un second plasmide, servant de plasmide de transfert, qui comprend une cassette de ribozymes contenant le domaine catalytique d'un ribozyme à autoépissage (intron de classe I) et une séquence codant la contrepartie adéquate de l'ARN cible à réparer, (c) un troisième plasmide comprenant une séquence codant VLV Pol, (d) un quatrième plasmide comprenant des séquences codant VLV Vif, Rev et Tat, (e) un cinquième plasmide comprenant une séquence codant une protéine d'enveloppe Env, qui n'est pas dérivée de VLV, les plasmides a et de c à e ne codant pas d'autres protéines VLV et ne contenant pas de signal d'emballage compétent.
PCT/EP2006/000358 2005-01-17 2006-01-17 Systeme de transfert de gene lentiviral pour une reparation de l'arn mediee par les ribozymes Ceased WO2006074963A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005003207.9 2005-01-17
DE200510003207 DE102005003207A1 (de) 2005-01-17 2005-01-17 Lentivirales Gentransfersystem für Ribozym-vermittelte RNA-Reparatur

Publications (2)

Publication Number Publication Date
WO2006074963A2 WO2006074963A2 (fr) 2006-07-20
WO2006074963A3 true WO2006074963A3 (fr) 2007-01-04

Family

ID=36084215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/000358 Ceased WO2006074963A2 (fr) 2005-01-17 2006-01-17 Systeme de transfert de gene lentiviral pour une reparation de l'arn mediee par les ribozymes

Country Status (2)

Country Link
DE (1) DE102005003207A1 (fr)
WO (1) WO2006074963A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2979919B1 (fr) 2011-09-12 2015-12-11 Centre Nat Rech Scient Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1
GB201906283D0 (en) * 2019-05-03 2019-06-19 Moredun Res Institute Vector

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055335A1 (fr) * 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Vecteurs lentiviraux pseudotypes et utilisations de ces vecteurs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055335A1 (fr) * 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Vecteurs lentiviraux pseudotypes et utilisations de ces vecteurs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERKOWITZ ROBERT D ET AL: "Gene transfer systems derived from Visna virus: Analysis of virus production and infectivity", VIROLOGY, vol. 279, no. 1, 5 January 2001 (2001-01-05), pages 116 - 129, XP002375761, ISSN: 0042-6822 *
BRAUN M J ET AL: "THE VISNA VIRUS GENOME EVIDENCE FOR A HYPERVARIABLE SITE IN THE ENV GENE AND SEQUENCE HOMOLOGY AMONG LENTIVIRUS ENVELOPE PROTEINS", JOURNAL OF VIROLOGY, vol. 61, no. 12, 1987, pages 4046 - 4054, XP002375760, ISSN: 0022-538X *
FULLER M ET AL: "Helper plasmids for production of HIV-1-derived vectors", HUMAN GENE THERAPY, vol. 12, no. 17, 20 November 2001 (2001-11-20), pages 2081 - 2093, XP002287261, ISSN: 1043-0342 *
LONG MEREDITH B ET AL: "Ribozyme-mediated revision of RNA and DNA.", JOURNAL OF CLINICAL INVESTIGATION, vol. 112, no. 3, August 2003 (2003-08-01), pages 312 - 318, XP002375762, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
DE102005003207A1 (de) 2006-07-27
WO2006074963A2 (fr) 2006-07-20

Similar Documents

Publication Publication Date Title
Graf et al. Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression
Masuda et al. Fate of HIV-1 cDNA intermediates during reverse transcription is dictated by transcription initiation site of virus genomic RNA
Coyle et al. The Tpr protein regulates export of mRNAs with retained introns that traffic through the Nxf1 pathway
Lin et al. Spacer-length dependence of programmed− 1 or− 2 ribosomal frameshifting on a U 6 A heptamer supports a role for messenger RNA (mRNA) tension in frameshifting
Smyth et al. In cell mutational interference mapping experiment (in cell MIME) identifies the 5′ polyadenylation signal as a dual regulator of HIV-1 genomic RNA production and packaging
RU2018122636A (ru) Стабильные клеточные линии для продуцирования ретровирусов
Chamanian et al. A cis-acting element in retroviral genomic RNA links Gag-Pol ribosomal frameshifting to selective viral RNA encapsidation
Grewe et al. The HIV-1 Rev protein enhances encapsidation of unspliced and spliced, RRE-containing lentiviral vector RNA
Wang et al. RNA incorporation is critical for retroviral particle integrity after cell membrane assembly of Gag complexes
Hanawa et al. Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors
AU2017225350B2 (en) Promoter
McLaren et al. Modulating HIV-1 RNA processing and utilization
Roberts et al. The 5′ RNA terminus of spleen necrosis virus stimulates translation of nonviral mRNA
Nappi et al. Identification of a novel posttranscriptional regulatory element by using a rev-and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap
WO2009087110A8 (fr) Peptides sécrétables inhibiteurs de l'entrée de vih pour une thérapie d'une infection par le vih
CN106636154A (zh) 高效sgRNA筛选系统和方法
Li et al. Lentiviral vector delivery of recombinant small interfering RNA expression cassettes
WO2006074963A3 (fr) Systeme de transfert de gene lentiviral pour une reparation de l'arn mediee par les ribozymes
Müllner et al. Identification of the Rem-responsive element of mouse mammary tumor virus
Ali et al. Role of Purine-Rich Regions in Mason-Pfizer Monkey Virus (MPMV) Genomic RNA Packaging and Propagation
Lee et al. Characterization of functional domains of equine infectious anemia virus Rev suggests a bipartite RNA-binding domain
Martinez tRNAs as primers and inhibitors of retrotransposons
Miyazaki et al. Structural dynamics of retroviral genome and the packaging
Lloyd et al. Characterization of HIV-1 integrase N-terminal mutant viruses
Kemler et al. The critical role of proximal gag sequences in feline immunodeficiency virus genome encapsidation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC - EPO FORM 1205A OF 02/10/2007

122 Ep: pct application non-entry in european phase

Ref document number: 06706260

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6706260

Country of ref document: EP